Editas Medicine
EDIT
264 hedge funds and large institutions have $591M invested in Editas Medicine in 2022 Q3 according to their latest regulatory filings, with 39 funds opening new positions, 73 increasing their positions, 75 reducing their positions, and 28 closing their positions.
39% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 28
27% more call options, than puts
Call options by funds: $23.8M | Put options by funds: $18.6M
5% more capital invested
Capital invested by funds: $561M → $591M (+$30.3M)
3% more funds holding
Funds holding: 256 → 264 (+8)
1.05% more ownership
Funds ownership: 69.17% → 70.22% (+1%)
3% less repeat investments, than reductions
Existing positions increased: 73 | Existing positions reduced: 75
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$27M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$10.1M |
| 3 |
Goldman Sachs
New York
|
+$5.11M |
| 4 |
Two Sigma Investments
New York
|
+$4.89M |
| 5 |
Man Group
London,
United Kingdom
|
+$4.82M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$23.9M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
-$12M |
| 3 |
NAMA
Nikko Asset Management Americas
New York
|
-$6.12M |
| 4 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
-$6.12M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$5.65M |
EDIT Hedge Fund Activity: Q3 2022 in Review
264 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Editas Medicine (EDIT) for Q3 2022, worth a combined $591M — up 5.4% from $561M a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new EDIT positions and 28 closed out — a net gain of 11 holders — while 73 added to existing stakes and 75 trimmed.
The largest buyer was Millennium Management, adding an estimated $27M. The largest seller was State Street, cutting an estimated $23.9M.
- 264 institutional investors held Editas Medicine (EDIT) as of Q3 2022, up from 256 in Q2 2022.
- Funds reported $591M of Editas Medicine stock for Q3 2022, up 5.4% quarter-over-quarter.
- 39 funds opened new Editas Medicine positions in Q3 2022 and 28 closed out, a net change of +11 holders.
- The largest Editas Medicine buyer in Q3 2022 was Millennium Management, an estimated $27M added.
- The largest Editas Medicine seller in Q3 2022 was State Street, an estimated $23.9M sold.
Based on aggregated 13F filings for Q3 2022.